Company intelligence / Profile preview
Keros Therapeutics
Lexington, Massachusetts, United Statesir.kerostx.com ↗
- Ownership
- Public · KROS
- Employees
- ~100
- Development stage
- Other
01
Overview
Keros has multiple clinical programs with elritercept (KER-050) in Phase 3 for MDS, cibotercept (KER-012) in Phase 2 for PAH (though dosing was halted due to pericardial effusion adverse events), and KER-065 in Phase 1 for neuromuscular diseases. The company recently licensed elritercept to Takeda for development outside mainland China, Hong Kong, and Macau.
- Therapeutic areas
- CardiovascularRheumatologyEndocrinologyHematologyRare Diseases
- Modalities
- Protein therapeuticsSmall moleculesRecombinant proteinsFusion proteinsAntibodiesBiological products
- Industry
- Biotech
02
Drug pipeline
11 assets10 more assets in the full pipeline.
03
Partnerships
Takeda Pharmaceuticals U.S.A., Inc. (exclusive license agreement for elritercept)Hansoh (Shanghai) Healthtech Co., Ltd.
04
Financials
- Market cap
- $187.4M
- Total revenue
- $244.1M
- Enterprise value
- $-57M
Beyond the preview
Go deeper on Keros Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Keros Therapeutics.